Curated News
By: NewsRamp Editorial Staff
October 26, 2026
Carl Zeiss Meditec Appoints Bronwyn Brophy O’Connor as CEO
TLDR
- Carl Zeiss Meditec gains a CEO with Medtronic and Thermo Fisher experience to accelerate transformation and sharpen customer-focused innovation.
- Bronwyn Brophy O'Connor becomes CEO of Carl Zeiss Meditec AG on December 1, 2026, succeeding interim CEO Andreas Pecher and joining the ZEISS AG Executive Board.
- New leadership at Carl Zeiss Meditec aims to advance patient care through innovative medical technologies and strong customer relationships.
- Bronwyn Brophy O'Connor, a Dublin City University alumna, has held leadership roles at Johnson & Johnson, Medtronic, Thermo Fisher, and Vitrolife.
Impact - Why it Matters
This leadership transition signals Carl Zeiss Meditec’s commitment to accelerating innovation and transformation in the medical technology sector. Bronwyn Brophy O’Connor’s extensive international experience and customer-focused approach are expected to drive growth and enhance patient care. For stakeholders, including investors, employees, and healthcare professionals, this change promises continuity and a renewed emphasis on advancing diagnostic and treatment solutions. As the medtech industry evolves, O’Connor’s strategic vision will be crucial in maintaining ZEISS’s competitive edge and delivering value to patients worldwide.
Summary
Carl Zeiss Meditec AG has confirmed that Bronwyn Brophy O’Connor will assume the role of CEO on December 1, 2026, succeeding Andreas Pecher, who has served as interim CEO since January 1, 2026. O’Connor will also join the Executive Board of Carl Zeiss AG, where she will oversee the Medical Technology segment. Her appointment had been initially announced in May 2026. O’Connor brings a wealth of experience from her current position as CEO of the Vitrolife Group in Sweden, as well as leadership roles at Johnson & Johnson, Medtronic, and Thermo Fisher Scientific. She holds an MBA from Dublin City University and has worked internationally across Ireland, Spain, the U.K., Switzerland, Sweden, and the U.S.
In her new role, O’Connor will focus on advancing innovation and driving the next stage of the company’s transformation. Peter Kameritsch, Chairman of the Supervisory Board of Carl Zeiss Meditec AG, praised her customer-focused and innovation-driven perspective, while Dr. Michael Bolle, Chairman of the Supervisory Board of Carl Zeiss AG, thanked Andreas Pecher for his interim leadership and expressed confidence in O’Connor’s ability to further the strategy of the Medical Technology segment. Effective December 1, 2026, the Management Board of Carl Zeiss Meditec AG will consist of O’Connor as CEO and Justus Wehmer as CFO. The Executive Board of Carl Zeiss AG will include Andreas Pecher as President and CEO, along with other segment heads.
Carl Zeiss Meditec AG, listed on the TecDAX and SDAX, is a leading medical technology company with 5,784 employees and revenue of EUR 2,228 million in fiscal year 2024/25. The company provides innovative technologies and solutions for diagnosing and treating eye diseases, as well as visualization solutions for microsurgery. With headquarters in Jena, Germany, and subsidiaries worldwide, the company maintains a strong global presence. For more information, visit www.zeiss.com/med or the www.zeiss.com/newsroom.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Carl Zeiss Meditec Appoints Bronwyn Brophy O’Connor as CEO
